Eslicarbazepine acetate - APTIOM tablets | GlobalRPh Renal Dosing Master

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Cautions / source differences (1)

Review first - source-specific qualification

Before use: Eslicarbazepine acetate - APTIOM tablets

The 50% reduction applies to initiation, titration and maintenance, not just the final daily dose.

Before applying: Confirm the exact product, indication, renal measure and full source before prescribing.

Evidence for this qualification

Source-specific interpretation; independent clinician adjudication pending.

Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.

Choose a source to read (1)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

Rxlist source

GlobalRPh RX List - APTIOM tablets

Product / population: Partial-onset seizures in patients at least 4 years old; pediatric base regimen remains weight-dependent.
Renal measure: Creatinine clearance, mL/min

RX mirror: this is not independent corroboration of its underlying label. Check dated-label and formulation limitations.

Renal guidance and important limits

Limits that apply to these rows

A percentage reduction does not replace the age/weight-specific starting regimen. Do not abruptly discontinue.

Monitor sodium when appropriate and assess symptoms of hyponatremia. Concomitant antiseizure-drug interactions require separate review.

No new official-label card was obtained for this product in v6.3. Earlier source layers, if present, were retained but not rechecked.

APTIOM renal modification
CrCl, mL/min	Source-specific dose / instruction
<50	Generally reduce initial, titration and maintenance dosages by 50%; individualize to response

Read the retained text before reformatting

APTIOM renal modification

CrCl, mL/min	Source-specific dose / instruction
<50	Generally reduce initial, titration and maintenance dosages by 50%; individualize to response

A percentage reduction does not replace the age/weight-specific starting regimen. Do not abruptly discontinue.

Monitor sodium when appropriate and assess symptoms of hyponatremia. Concomitant antiseizure-drug interactions require separate review.

Source revision: 3/2019 | Retrieved: 2026-09-10. Retrieval date is not the revision date.

Source: https://globalrph.com/rx-list/aptiom-drug/

Scope: Selected source sections stored locally. Not a complete monograph or independent clinical approval. GlobalRPh v6.6.

Full source card / provenance

All sources, comparison tools and evidence navigation

Source-specific interpretation

What the dialysis evidence actually supports

Removal information alone does not define a maintenance dose, supplemental dose or dialysis schedule. A reported regimen still requires its product, indication, renal measure and dialysis assumptions to match the patient.

GlobalRPh RX List - APTIOM tablets

Authored v6.3; retrieved 2026-09-10 - retained source, not freshly reviewed in this release

No dialysis regimen established in selected content

Read the source and its limits

These manual classifications apply only to the identified selected sections, not every retained source or the entire prescribing information. They are not dosing clearance.

Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Read 1 source difference / applicability notes

GlobalRPh RX List

GlobalRPh RX List - APTIOM tablets

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Before using this finding

Confirm the exact product, indication, renal measure and full source before prescribing.

Dialysis evidence: No dialysis regimen established in selected content

Partial-onset seizures in patients at least 4 years old; pediatric base regimen remains weight-dependent.

Renal method: Creatinine clearance, mL/min
Retrieved: 2026-09-10

Read local renal resultOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Find text within this drug

Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. Searches stay on this page and are not saved or sent.

All source summaries, original wording and provenance

Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources

Jump to renal guidance Read 1 difference / caution notes Clinician guide

Only one eligible source version is stored here. No second source is inferred from a reference link. Independent corroboration is still needed.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Source-review outline (read-only; copy and complete elsewhere)

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Population Kidney-function trend Renal replacement setting

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Read before choosing a regimen

Source differences and product cautions

Search differences across all drugs

These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.

source scope and renal guidance

Before use: Eslicarbazepine acetate - APTIOM tablets

The 50% reduction applies to initiation, titration and maintenance, not just the final daily dose.

How to use this: Confirm the exact product, indication, renal measure and full source before prescribing.

GlobalRPh RX List - APTIOM tablets

Source-specific interpretation; independent clinician adjudication pending.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

New source summary - independent clinical review pending. Summaries of the identified label sections are included locally. Source import and numeric transcription checks are not independent two-reference validation. Do not treat this card as an approved institutional dosing protocol.

Rxlist source

GlobalRPh RX List - APTIOM tablets

Partial-onset seizures in patients at least 4 years old; pediatric base regimen remains weight-dependent.

Method: Creatinine clearance, mL/min

Renal guidance and important limits Read this complete source summary

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scope GlobalRPh RX List - APTIOM tablets

Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.

Locally stored source content

Exact product and population

Product identity selected for the separately displayed source protocols below. Reference: https://globalrph.com/rx-list/aptiom-drug/

Exact product and population

Partial-onset seizures in patients at least 4 years old; pediatric base regimen remains weight-dependent.

RDM63-SCOPE-eslicarbazepine · Source section: Selected source product scopeRenal section finder

Locally imported selected renal sections

GlobalRPh RX List renal information

Rxlist Compare this source

GlobalRPh RX List - APTIOM tablets

Open original reference

Open / share this exact local source

GlobalRPh-hosted RX List · Partial-onset seizures in patients at least 4 years old; pediatric base regimen remains weight-dependent.

Renal method: Creatinine clearance, mL/min
Source date: 3/2019
Retrieved: 2026-09-10

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Before using this finding

Confirm the exact product, indication, renal measure and full source before prescribing.

Dialysis evidence: No dialysis regimen established in selected content

Selected source sections stored locally. Not a complete monograph or independent clinical approval.

Renal guidance and important limits

Limits that apply to these rows

A percentage reduction does not replace the age/weight-specific starting regimen. Do not abruptly discontinue.

Monitor sodium when appropriate and assess symptoms of hyponatremia. Concomitant antiseizure-drug interactions require separate review.

No new official-label card was obtained for this product in v6.3. Earlier source layers, if present, were retained but not rechecked.

APTIOM renal modification
CrCl, mL/min	Source-specific dose / instruction
<50	Generally reduce initial, titration and maintenance dosages by 50%; individualize to response

Read the retained text before reformatting

APTIOM renal modification

CrCl, mL/min	Source-specific dose / instruction
<50	Generally reduce initial, titration and maintenance dosages by 50%; individualize to response

A percentage reduction does not replace the age/weight-specific starting regimen. Do not abruptly discontinue.

Monitor sodium when appropriate and assess symptoms of hyponatremia. Concomitant antiseizure-drug interactions require separate review.

RDM63-rxlist-eslicarbazepine-9be76c97af-C1 · Source locator: Dosage modifications in renal impairment; hyponatremia; discontinuation

Source-specific limits

A percentage reduction does not replace the age/weight-specific starting regimen. Do not abruptly discontinue.

Monitor sodium when appropriate and assess symptoms of hyponatremia. Concomitant antiseizure-drug interactions require separate review.

No new official-label card was obtained for this product in v6.3. Earlier source layers, if present, were retained but not rechecked.

Source identity and provenance

Source family: product_label_mirror
Source: https://globalrph.com/rx-list/aptiom-drug/
Retrieved: 2026-09-10
Renal-function method: Creatinine clearance, mL/min
Source date/version: 3/2019
Hash meaning: Local authored summary, not source HTML/XML/PDF bytes
Local summary SHA-256: 39b65209c0d362ac091329cd6bb2eb7784fa1249d0ed21ac60ba42da103fffbe

Provenance and preservation

Additional summaries stored on this page: 0 official-label, 1 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source: https://globalrph.com/rx-list/aptiom-drug/
Source retrieval: 2026-09-10. This is not the source publication or label revision date.
Original source type: rxlist summary
Local text SHA-256: 4a4023b48976c24ff311cfb4b7e43f6402f222e925369e4190937fd1c712efa4
Import versus clinical validation: Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.

Read the full coverage report